Do SGLT-2 Inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?

Do SGLT-2 Inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?

Bibliographic Details
Main Authors:	Antonio De Pascalis, MD, Giuseppe Cianciolo, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	Kidney Medicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2590059520301151

Similar Items

In Reply to ‘Do SGLT-2 Inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?’
by: Hannes Neuwirt, MD, et al.
Published: (2020-07-01)

Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor Therapy
by: Hannes Neuwirt, et al.
Published: (2020-01-01)

Modelling nephron dynamics and tubuloglomerular feedback
by: Graybill, Scott Jason
Published: (2010)

Modelling tubuloglomerular feedback in coupled nephrons
by: Hattaway, Amanda L
Published: (2004)

The Influence of the Adenosine A1-receptor on Tubuloglomerular Feedback and Renin Release
by: Brown, Russell
Published: (2004)

SGLT2 Inhibitor–Induced Sympathoinhibition
by: Lakshini Y. Herat, PhD, et al.
Published: (2020-02-01)

Interactions between adenosine, angiotensin II and nitric oxide on the afferent arteriole influence sensitivity of the tubuloglomerular feedback
by: A. Erik G Persson, et al.
Published: (2013-07-01)

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?∗
by: Subodh Verma, MD, PhD
Published: (2020-02-01)

Mineral and Electrolyte Disorders With SGLT2i Therapy
by: Giuseppe Cianciolo, et al.
Published: (2019-11-01)

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
by: Jiyoung Park, et al.
Published: (2019-05-01)

The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i
by: Giuseppe Cianciolo, et al.
Published: (2020-06-01)

Euglycemic diabetic ketoacidosis: The clinical concern of SGLT2 inhibitors
by: Jamila A. Benmoussa, MD, et al.
Published: (2016-12-01)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
by: Simes BC, et al.
Published: (2019-10-01)

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
by: Adel E. Berbari
Published: (2020-12-01)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
by: Lea El Hage MD, et al.
Published: (2019-12-01)

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
by: Ven G. Lim, MBChB, et al.
Published: (2019-02-01)

“The Proof is in the Pudding”: Do SGLT2 Inhibitors Cause Diabetic Ketoacidosis?
by: Elena Barengolts, MD
Published: (2018-03-01)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
by: Natalia G. Vallianou, et al.
Published: (2021-06-01)

Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation
by: Motoaki Sano
Published: (2020-07-01)

SODIUM GLUCOSE COTRANSPORT(SGLT2) INHIBITORS. A NEW TYPE OF ANTIDIABETICS BY ORAL ADMINISTRATION
by: Gloria Viñes, et al.
Published: (2014-12-01)

Fournier's gangrene and sodium-glucose co-transporter 2(SGLT2) inhibitors: Our experience
by: Ashwitha S Dass, et al.
Published: (2019-01-01)

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor drugs: Assessment of safety in Fasting Diabetics
by: Muhammad Imran Hasan Khan, et al.
Published: (2021-03-01)

Renoprotective Effects of SGLT2 Inhibitors
by: Guja Cristian, et al.
Published: (2019-06-01)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
by: Alex Ali Sayour, et al.
Published: (2021-09-01)

Outflows as feedback mechanism in galaxies
by: Cicone, Claudia
Published: (2015)

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
by: Carlo Garofalo, et al.
Published: (2019-06-01)

Safe and pragmatic use of sodium-glucose co-transporter 2 (SGLT 2) inhibitors: medication counseling
by: S. Kalra, et al.
Published: (2016-08-01)

Quality of methodological reporting of randomized clinical trials of sodium-glucose cotransporter-2 (sglt2) inhibitors
by: Hadeel Alfahmi, et al.
Published: (2017-01-01)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
by: Beatriz Fernandez-Fernandez, et al.
Published: (2020-06-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States
by: Aggarwal, R., et al.
Published: (2022)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
by: Zsolt Szekeres, et al.
Published: (2021-02-01)

SGLT-2 inhibitors and their potential in the treatment of diabetes
by: Rosenwasser RF, et al.
Published: (2013-11-01)

Recommendations on the Proper Use of SGLT2 Inhibitors
by: The Committee on the Proper Use of SGLT2 Inhibitors
Published: (2020-01-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
by: Derosa G, et al.
Published: (2018-09-01)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents
by: Eva M Vivian
Published: (2014-12-01)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
by: Sanjay Kalra, et al.
Published: (2015-01-01)

Radiofrequency Catheter Ablation of Idiopathic Right Ventricular Outflow Tract Arrhythmias
by: Naiara Calvo, MD, et al.
Published: (2013-01-01)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
by: Hang-Long Li, et al.
Published: (2021-05-01)